Gerald V. Denis, PhD, Named Shipley Prostate Cancer Research Professor
Gerald V. Denis, PhD, has been named the Shipley Prostate Cancer Research Professor effective September 1, and will represent the molecular oncology themes of the Center. Dr. Denis has been a member of the BU faculty for 23 years, during which time he pioneered studies of the Bromodomain and ExtraTerminal (BET)... More
Gerald Denis, PhD, Promoted to Professor of Medicine and Pharmacology
We are delighted to announce that BU-BMC Co-Director Gerald Denis, PhD, has been promoted to the rank of Professor of Medicine and Pharmacology. Gerald is a noted expert in the field of BET bromodomain proteins, and his work has gained broad influence nationally and internationally in the emerging areas of... More
Julie Palmer Quoted in Fortune Magazine “We can’t ever go to the doctor with our guard down”: Why Black Women are 40% More Likely to Die of Breast Cancer
Julie Palmer, ScD, Director of BU's Slone Epidemiology Center and Co-Director of BU-BMC Cancer Center quoted in Fortune Magazine article: ‘We can’t ever go to the doctor with our guard down’: Why Black women are 40% more likely to die of breast cancer
Cancer Center Retreat
The Cancer Center Retreat was held on February 28. The event included the Center Director’s report, presentation of the Center’s four research programs, selected lightning talks, a presentation from the Translational Oncology Core (CTAP) and a poster session highlighting tools and resources that are available to the research community. Retreat... More
BU and Johnson & Johnson Innovation Team Up to Fight Lung Cancer
Tuesday, June 6, 2018 Written by: Sara Rimer and Art Jahnke | Source: BUToday New Medical Campus center hopes to speed development of interventions and cures In what Boston University President Robert A. Brown envisions as a model for industry and academia collaborating to improve human health, BU has launched a five-year translational research alliance with... More
BET Proteins Exhibit Transcriptional and Functional Opposition in the Epithelial-to-Mesenchymal Transition
Published April 2018 Provided by: American Association for Cancer Research Publications | Source: Molecular Cancer Research Guillaume P. Andrieu and Gerald V. Denis DOI: 10.1158/1541-7786.MCR-17-0568 Abstract Transcriptional programs in embryogenesis and cancer, such as the epithelial-to-mesenchymal transition (EMT), ensure cellular plasticity, an essential feature of carcinoma progression. As effectors of signal transduction, the bromodomain and extraterminal... More
BU-CTSI Fall 2017 Pilot Awardees
Monday, March 5, 2018 Provided by: Boston University Clinical & Translational Science Institute | Source: CTSI Boston University Clinical and Translational Science Institute (BU-CTSI) is pleased to announce the recipients of the Fall 2017 Integrated Pilot Grant Program. Each awardee received $20,000 in funding. The CTSI would like to recognize the faculty who reviewed the applicants... More
Insight into chromatin therapies for breast cancer could aid personalized medicine
Wednesday, February 7, 2018 Provided by: Boston University School of Medicine | Source: Medical Xpress Most traditional chemotherapy for cancer has dangerous side effects, but new research is finding ways to develop 'targeted agents' that reduce the side effects and are better tailored to individual patient needs. While these innovations are exciting, a new study shows... More
2018 Dahod International Scholar
Friday, February 2, 2018 Kristyna Kotýnková, PhD, has been named the 2018 Dahod International Scholar. In August 2008 Shamim Dahod (CGS'76, CAS'78, MED'87) and her husband Ashraf gave $10.5 million to BUSM to establish the Shamim and Ashraf Dahod Breast Cancer Research Center, as well as endow assistant professorships and international... More
Avrum Spira Leads “Stand Up to Cancer” Dream Team
Wednesday, November 1, 2017 Written by: Sara Rimer | Source: BUToday Armed with $12 million, researchers aim for early detection of lung cancer Can lung cancer, rarely diagnosed until it’s in an advanced and deadly stage, be nipped in the bud? Avrum Spira and his team intend to find out. Spira (ENG’02), Alexander Graham Bell Professor in Health... More